A clinical trial ends. The data looks promising. The drug helped. And then, suddenly, access stops. For some trial participants, this moment raises a difficult question: what happens next? The drug is not yet approved by the FDA, it is not available at a pharmacy, and the trial is closing. The gap between trial completion and FDA approval can last months or years. Fortunately, several legal pathways exist to maintain access to investigational medications during this wait - but each works differently, and eligibility varies.
Understanding the Trial End Timeline
When a Phase 3 trial reaches its completion date, the company managing the trial must decide what happens next. Sometimes the drug has already been submitted to the FDA for approval. Sometimes approval is still months away. Sometimes the trial results are being analyzed, and submission will come later. The company may choose to close the trial immediately, or it may offer participants ways to continue receiving the drug during the approval process.
The most common path is an open-label extension. But if the company does not offer one, or if a participant does not qualify, other options exist. Understanding these pathways - and asking about them before a trial ends - can be the difference between continuous access and a sudden loss of treatment.
1. Open-Label Extensions (OLEs)
An open-label extension is a continuation of a clinical trial in which all participants know they are receiving the active drug (no placebo), and they continue to be monitored for safety and efficacy. OLEs are the most common way patients maintain access to an investigational drug between trial completion and FDA approval.
In trials for rare diseases, OLEs are routine. According to FDA guidance and industry data, roughly 90% or more of pivotal rare disease trials include OLE provisions. Participants simply transition from the randomized phase of the trial (where some may have received placebo) into the open-label phase, where everyone receives the active drug. This can continue for months or even years while the company pursues approval.
OLEs are not automatic, though. The company must design them into the trial protocol from the start, and they require ongoing FDA oversight. Participants typically must continue to visit the trial site regularly, provide blood samples or other monitoring data, and meet the same eligibility criteria they did for the original trial. If the drug is approved during an OLE, the program closes and patients transition to using the approved medication.
2. Expanded Access (Compassionate Use)
Expanded access, also called compassionate use, is an FDA pathway that allows patients with serious or life-threatening conditions to access investigational drugs outside of clinical trials. It exists specifically to serve patients who have exhausted all standard treatment options and may benefit from an investigational medication.
The regulatory authority for expanded access is 21 CFR 312.310. There are 3 types: individual patient (for single patients, either emergency or non-emergency), intermediate-size patient programs (for clusters of similar patients), and treatment INDs or protocols (broader programs for larger patient populations). Physicians or the drug manufacturer can submit an expanded access request to the FDA.
According to FDA data, the approval rate for expanded access is striking: emergency requests are approved in over 99% of cases within 24 hours. Non-emergency requests also have very high approval rates. This does not mean access is guaranteed, however. The drug manufacturer must agree to provide the medication; the FDA cannot compel them to do so. If a company decides not to supply an investigational drug under expanded access, the door closes.
Expanded access typically requires a physician to initiate the request, meaning patients need an advocate - usually their own doctor - to push for it. The physician must provide medical justification and demonstrate that standard treatments have been exhausted. Once approved, the manufacturer supplies the drug, often at no cost, though there is no legal guarantee of free access.
3. Right to Try Act
The Right to Try Act was signed into law on May 30, 2018. It creates a legal pathway for terminally ill patients to request investigational drugs directly from manufacturers, bypassing the FDA review process entirely. To qualify, patients must have a terminal illness that has exhausted all FDA-approved treatment options.
The key difference between Right to Try and expanded access is speed and autonomy. Under Right to Try, patients can request the drug directly; the FDA does not need to approve the request. The manufacturer can say no, but there is no bureaucratic delay or regulatory review. For some families facing a terminal diagnosis, this speed feels critical.
According to Right to Try program data, actual usage has been limited. Between 2018 (when the law took effect) and 2023, fewer than 20 patients per year used Right to Try nationally. The reasons are complex: many manufacturers still refuse access even under Right to Try; the requirement for terminal illness excludes most trial participants; patients and their doctors often are not aware of the law; and by the time it is considered, patients may be too sick to undergo treatment.
4. Treatment IND Programs
A treatment IND (Investigational New Drug) is a formal FDA pathway that makes an investigational drug available to wider patient populations while the company's New Drug Application (NDA) or Biologics License Application (BLA) is under FDA review. It bridges the gap between successful trial completion and final approval.
Unlike expanded access, which is typically for individual or small groups of patients, a treatment IND can be a fairly large program. It allows the drug company to continue supplying the medication to trial participants and expand to patients who did not participate in the trial but meet the same clinical criteria. Treatment INDs generate additional safety data while FDA reviewers evaluate the full application.
A notable historical example is imatinib (branded as Gleevec), a breakthrough cancer drug. Gleevec was made available through a treatment IND program before its FDA approval in 2001, allowing a broader set of chronic myeloid leukemia patients to receive the medication while the agency completed its review. This approach is common for serious and life-threatening diseases where waiting for FDA approval feels untenable.
The Gap Between Trial End and FDA Approval
Even after a Phase 3 trial succeeds, there are delays. The company must analyze the data, prepare the regulatory submission, and submit to the FDA. Per FDA guidelines, review itself takes time: standard review is 10 months, and priority review is 6 months. But the clock does not start on approval day; it starts on submission day. Between trial completion and submission, weeks or months may pass.
For rare diseases, the timeline can stretch further. Pediatric and adolescent populations add layers of complexity. Manufacturing scale-up, if the drug is approved, requires time and investment. And if the FDA issues a Complete Response Letter (asking for additional data or studies), the entire timeline extends.
How to Advocate for Continued Access
If a trial is nearing completion, proactive conversation is key. Trial participants should ask their research coordinator or principal investigator several specific questions months before the trial ends.
First: Is the company planning an open-label extension? If yes, what is the timeline, and how long might it last? Second: If no OLE is planned, is the company open to expanded access requests for participants who benefited from the drug? Third: When does the company plan to submit the drug for FDA approval, and how long might review take? Fourth: Will insurance cover the medication if it is approved, and what is the company's strategy for pricing and access? These conversations take time but can prevent a crisis when the trial suddenly closes.
Patients should also consider connecting with disease-specific advocacy groups. These organizations often have relationships with manufacturers and can help escalate access requests or provide guidance on navigating the approval process. They also sometimes have data on which companies are cooperative with expanded access and which are not.
Key Takeaways
The end of a clinical trial is not necessarily the end of access to the medication. But it requires planning, advocacy, and understanding of the pathways available. Open-label extensions are routine in rare disease but less common in other areas. Expanded access has a very high approval rate but depends on manufacturer cooperation. Right to Try is fast but limited to terminal illness and faces real barriers to use. Treatment INDs offer a formal bridge but require manufacturer initiative.
For patients and families, the lesson is clear: ask questions early, understand what the company is planning, know the options, and consider reaching out to disease advocacy groups. You can search for active clinical trials by disease on Trial Friend to understand what's currently available. The gap between trial completion and FDA approval can feel like a chasm, but several legal pathways exist to cross it. Knowing them, and pushing for them when needed, can mean the difference between continuous access and a sudden loss of treatment.